7.45

0.07% 0.005

After Hours: 7.45

Anavex Life Sciences Corporation (AVXL)

Overview News Price History Option Chain Financials Why AVXL Down? Discussions Forecast Stock Split

Anavex Life Sciences Corporation stock is traded at $7.45, with a volume of 1.44M. It is up +0.07% in the last 24 hours and up +31.86% over the past month. Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Previous Close:

$7.445

Open:

$7.59

24h Volume:

1.44M

Relative Volume:

1.56

Market Cap:

$630.58M

Revenue:

Net Income/Loss:

$-43.16M

P/E Ratio:

-11.29

EPS:

-0.66

Net Cash Flow:

$-29.31M

1W Performance:

-18.58%

1M Performance:

+31.86%

6M Performance:

+63.74%

1Y Performance:

+18.82%

1-Day Range:

$7.18

$7.60

1-Week Range:

$7.18

$9.5975

52-Week Range:

$3.25

$10.45

Anavex Life Sciences Corporation Stock (AVXL) Company Profile

Name

Anavex Life Sciences Corporation

Sector

Healthcare (1196)

Industry

Biotechnology (683)

Phone

844-689-3939

Address

630 5TH AVENUE, NEW YORK

Employee

Twitter

@anavexlifesci

Next Earnings Date

2024-11-25

Latest SEC Filings

AVXL's Discussions on Twitter

Compare AVXL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVXL	7.45	630.58M	0	-43.16M	-29.31M	-0.66
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-23-22	Initiated	Berenberg	Buy
Sep-23-21	Initiated	BTIG Research	Buy
Dec-16-20	Reiterated	H.C. Wainwright	Buy
Sep-28-20	Initiated	Ladenburg Thalmann	Buy
Feb-27-20	Initiated	Cantor Fitzgerald	Overweight
Jun-18-19	Initiated	Janney	Buy
May-16-18	Resumed	Maxim Group	Buy
Mar-08-18	Initiated	ROTH Capital	Buy
Feb-13-18	Reiterated	Maxim Group	Buy
Sep-29-17	Resumed	Noble Financial	Buy
Feb-07-17	Initiated	Noble Financial	Buy
Mar-29-16	Initiated	FBR Capital	Outperform

View All

Anavex Life Sciences Corporation Stock (AVXL) Latest News

Nov 13, 2024

Contrasting Palisade Bio (NASDAQ:PALI) & Anavex Life Sciences (NASDAQ:AVXL) - Defense World

Nov 13, 2024

Nov 11, 2024

Anavex Life Sciences (NASDAQ:AVXL) Reaches New 52-Week HighShould You Buy? - MarketBeat

Nov 11, 2024

Nov 08, 2024

Anavex Life Sciences (NASDAQ:AVXL) Shares Up 8.1%Here's Why - MarketBeat

Nov 08, 2024

Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla? - Benzinga

Nov 08, 2024

Nov 06, 2024

Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario - Seeking Alpha

Nov 06, 2024

Nov 04, 2024

HC Wainwright Reiterates "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat

Nov 04, 2024

Nov 01, 2024

Loss-Making Anavex Life Sciences Corp. (NASDAQ:AVXL) Expected To Breakeven In The Medium-Term - Simply Wall St

Nov 01, 2024

Oct 31, 2024

Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 - The Manila Times

Oct 31, 2024

Oct 18, 2024

NY Biopharma Shares Promising Clinical Data - Streetwise Reports

Oct 18, 2024

Anavex Life Sciences (NASDAQ:AVXL) Rating Reiterated by HC Wainwright - MarketBeat

Oct 18, 2024

Oct 17, 2024

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - StockTitan

Oct 17, 2024

Oct 15, 2024

Short Interest in Anavex Life Sciences Corp. (NASDAQ:AVXL) Declines By 10.3% - MarketBeat

Oct 15, 2024

Oct 10, 2024

Examining Anavex Life Sciences Corporation (AVXL) stock is warranted - US Post News

Oct 10, 2024

Oct 09, 2024

Anavex Life Sciences Corp (AVXL) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance

Oct 09, 2024

Market Insights: Anavex Life Sciences Corporation (AVXL)’s Notable Drop of -2.42, Closing at 5.24 - The Dwinnex

Oct 09, 2024

Understanding the Risks of Investing in Anavex Life Sciences Corporation (AVXL) - Knox Daily

Oct 09, 2024

Oct 08, 2024

Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade) (NASDAQ:AVXL) - Seeking Alpha

Oct 08, 2024

Oct 03, 2024

The time has not yet come to remove your chips from the table: Anavex Life Sciences Corporation (AVXL) - SETE News

Oct 03, 2024

Renaissance Technologies LLC Has $1.97 Million Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat

Oct 03, 2024

Oct 01, 2024

A stock that deserves closer examination: Anavex Life Sciences Corporation (AVXL) - US Post News

Oct 01, 2024